(PharmaNewsWire.Com, July 10, 2017 ) Europe Renal Disease Therapeutics Market was worth $ xxx billion in 2016 and estimated to reach $ xxx billion by the end of 2021 with a CAGR of xxx %. Europe is accounted to have the second highest share in the market owing to increasing awareness about the renal diseases.
Kidney diseases are due to improper functioning of the kidneys and associated renal system over a longer period of time because of its high incidence of Diabetic cases, and high blood pressure. Kidneys have numerous functions, such as maintaining balance of water and minerals, such as potassium, sodium, and phosphorus in the blood, remove waste by-products from the blood after digestion, muscle activity, and exposure to chemicals or medications. When any form of damage to kidney occurs, they ultimately lose their vital function, which is fatal.
Europe Renal Disease Therapeutics Market is primarily driven by growing aging population, increasing number of individuals with insurance due to the Affordable Care Act, Increasing Diabetic Population, growing awareness of both acute and chronic kidney disease, and growing demand for the advanced diagnostics and therapeutics for the disease. Disparities of Renal Transplant Therapy, expiring of patents of some of the branded drugs for the late stage CKD and changing reimbursement scenario in some of major countries, Negative Societal Effects are the factors hindering the growth of the market.
The Europe Renal Disease Therapeutics market is segmented based on the Application, and treatment. Application mode is segmented into Kidney Stone Disease, End-Stage Kidney Disease, Kidney Failure, Chronic Kidney Disease, Hypertension, Diabetes, and Anaemia. The treatment segment is further categorized into Dialysis Equipment, Renal Denervation devices, Wearable artificial kidney device, and distal embolic protection devices. On the basis of geography, the Europe Renal Disease Therapeutics market is analysed under various regions namely U.K, Germany, France, Italy, and Spain.
Some of the key players influencing the Europe Renal disease Therapeutics market are Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Hoffmann-La Roche Inc., Shire Inc., Fresenius Medical Care, Baxter International, Davita Healthcare Partners.
About Market Data Forecast: The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering Global among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: